Status:
COMPLETED
Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305
Lead Sponsor:
AstraZeneca
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
20-80 years
Phase:
PHASE2
Brief Summary
This study is being carried out to see which dose of AZD1305 is safe and effective in cardioverting atrial fibrillation into normal heart rhythm.
Eligibility Criteria
Inclusion
- Clinical indication for cardioversion of Atrial Fibrillation, ie a correction of irregular heart rhythm to normal heart rhythm
- Current episode of Atrial Fibrillation (ie irregular heart rhythm) lasting up to 3 months at randomisation
- Adequate anticoagulation according to international guidelines (ACC/AHA/ESC, 2006) or national guidelines
Exclusion
- Potassium level below 3.8 mmol/L measured in serum or plasma
- QTcF interval \>440 ms
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
228 Patients enrolled
Trial Details
Trial ID
NCT00915356
Start Date
May 1 2009
End Date
December 1 2009
Last Update
February 1 2012
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Brno, CZ, Czechia
2
Research Site
Prague, Czechia
3
Research Site
Znojmo, Czechia
4
Research Site
Aalborg, Denmark